Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Apr 20, 2020
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights Mar 30, 2020
Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program Mar 23, 2020
Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights Mar 16, 2020
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights Mar 11, 2020
Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option Feb 24, 2020
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106 Feb 18, 2020
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA Feb 13, 2020
